Taysha Gene Therapies, Inc. (TSHA)
Develops gene therapies to treat rare inherited brain and nerve diseases.
$5.48-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+108.2%
The outlook
TSHA is trading near the middle of its 52-week range with strong analyst support—the consensus leans "Strong Buy" across 13 analysts. The average price target sits roughly 140% above the current price, though the stock's near-term trend remains mixed against its moving averages. The overall sentiment is bullish, but price action hasn't yet caught up to analyst expectations.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 13 analysts
Price trendMixed vs its moving averages
52-week range62% of the way from its 52-week low to high
Price targetAvg target +140% vs current price
Analyst price target
~12-month · 13 analysts$13.15average target+140.3% vs now
Now $5.48
Low $10.00High $19.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.57B
52-wk high
$7.30
52-wk low
$2.54
50-day avg
$5.96
200-day avg
$5.24
Trailing P/E
—